ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

PREVALENCE AND PREDICTORS OF CHEMO THERAPY INDUCED PERIPHERAL NEUROPATHY IN CANCER PATIENTS: A SYSTEMATIC REVIEW STUDY

Dr. Abdul Wasay, Dr. Usbah Khalid, Dr. Afshan Fayyaz

Abstract: Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting from chemo-therapy treatment for cancer. Severe acute CIPN may require chemotherapy dose reduction or cessation. There is no effective CIPN prevention strategy; treatment of established chronic CIPN is limited, and the prevalence of CIPN is not known. Method: Embase, Medline, CAB Abstracts, CINAHL, PubMed central, Cochrane Library, and Web of Knowledge for relevant references were used and used random-effects meta-regression to estimate overall prevalence. We assessed study quality using the CONSORT and STROBE guidelines, and we report findings according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance. Results: We provide a qualitative summary of factors reported to alter the risk of CIPN.31 studies with 4179 patients were used in the study. Data from CIPN prevalence was 68.1% (57.7–78.4) when measured in the first month after chemotherapy, 60.0% (36.4–81.6) at 3 months and 30.0% (6.4–53.5) at 6 months or more. Different chemotherapy drugs were associated with differences in CIPN prevalence. Genetic risk factors were reported in 4 studies. Clinical risk factors, identified in 4 of 31 studies, included neuropathy at baseline, smoking, abnormal creatinine clearance, and specific sensory changes during chemotherapy. Conclusion: CIPN prevalence decreases with time, at 6 months 30% of patients continue to suffer from CIPN. Routine CIPN surveillance during post-chemotherapy follow-up is needed. A number of genetic and clinical risk factors were identified that require further study. Key words: Chemotherapy-induced peripheral neuropathy (CIPN), Prevalence, Risk factors.

FULL TEXT